14.54

2.55% -0.38

Abivax ADR (ABVX)

Overview News Price History Discussions Forecast

Abivax ADR stock is currently priced at $14.54, with a 24-hour trading volume of 30,339. It has seen a -2.55% decreased in the last 24 hours and a -2.68% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $14.72 pivot point. If it approaches the $14.44 support level, significant changes may occur.

Previous Close:

$14.92

Open:

$14.88

24h Volume:

30,339

Market Cap:

$914.82M

Revenue:

Net Income/Loss:

$-159.39M

P/E Ratio:

EPS:

Net Cash Flow:

$-105.22M

1W Performance:

-7.86%

1M Performance:

-2.68%

6M Performance:

+43.96%

1Y Performance:

+0.00%

1D Range:

$14.32

$15.10

52W Range:

$7.995

$17.02

Abivax ADR Stock (ABVX) Company Profile

Name

Abivax ADR

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

33 1 53 83 09 63

Address

7-11 boulevard Haussmann, Paris

Employee

Twitter

Next Earnings Date

2024-05-30

Latest SEC Filings

ABVX's Discussions on Twitter

Abivax ADR Stock (ABVX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-14-23	Initiated	Leerink Partners	Outperform
Nov-14-23	Initiated	Morgan Stanley	Equal-Weight

Abivax ADR Stock (ABVX) Latest News

Stocks To Watch: Energy Market Drama And Financial Earnings Headline Holiday Week

Seeking Alpha

Abivax ADR Stock (ABVX) Financials Data

Abivax ADR (ABVX) Net Income 2024

ABVX net income (TTM) was -$159.39 million for the quarter ending December 31, 2023, a -221.55% decrease year-over-year.

Abivax ADR (ABVX) Cash Flow 2024

ABVX recorded a free cash flow (TTM) of -$105.22 million for the quarter ending December 31, 2023, a -98.36% decrease year-over-year.

Abivax ADR (ABVX) Earnings per Share 2024

ABVX earnings per share (TTM) was -$3.5401 for the quarter ending December 31, 2023, a -13.17% decline year-over-year.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.